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Abstract:
Background:
Both the anti-infective and anti-inflammatory properties of vitamin D, an essential hormone of calcium homeostasis, have ample
support in the literature. The high rates of vitamin D deficiency among patients with chronic hepatitis C are also well known. That
supplementation with vitamin D may boost sustained viral response rates in vitamin D deficient, hepatitis C virus (HCV) infected
patients undergoing Interferon-alpha (IFN) treatment, on the other hand, is controversial. Surprisingly, studies considering in this
latter setting what are the effects of IFN treatment (with or without vitamin D supplementation) on the other major regulator of
mineral metabolism, i.e. the Parathyroid hormone (PTH), are lacking.
Aim:
Evaluate  the  impact  of  interferon-based  treatment  against  HCV  (±cholecalciferol  supplementation)  on  vitamin  D  and  PTH
homeostasis.
Methods:
A series  of  40 consecutive patients  received pegylated IFN plus ribavirin to  treat  chronic hepatitis  C.  At  the discretion of  their
physician, some of them (N. = 27) received vitamin D supplementation while others did not (N. = 13). All had measured plasma 25-
hydroxycholecalciferol and PTH concentrations at baseline, at completion of the 4th (TW4) and 12th treatment week (TW12) and at 24
weeks after the end of therapy (SVR24).
Results:
Plasma  PTH  concentration  increased  significantly  from  baseline  during  treatment,  raising  to  44.8  [30.7-57.2]  pg/mL  at  TW4
(p=0.01), 47.0 [37.1-63.2] pg/mL at TW12 (p=0.006) to return to baseline levels in the follow-up (34.5 [27.6-43.0]; p=0.16). The
proportion of patients who satisfied criteria for hyperparathyroidism was higher at TW12 (N=10, 25%) than at TW4 (N=6, 15%).
There was no statistical correlation between vitamin D and PTH blood levels (ρ=-0.07; p=0.65).
Conclusion:
An increase in plasma PTH occurs systematically during IFN treatment of HCV patients and cannot be prevented by vitamin D
supplementation.
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1. INTRODUCTION
Chronic hepatitis C is one of the most widespread liver diseases in the world, with over 170 million individuals
infected with the hepatitis C virus (HCV) and 3-4 million new cases every year [1, 2]. Before the introduction of the
Direct-Acting Antivirals (DAAs) [3], the standard of care consisted of the combination of Pegylated (PEG) Interferon-
alfa (IFN) and ribavirin administered for a period of 24 or 48 weeks, depending on HCV genotype [4]. Besides the
virus, the efficacy of IFN treatment is influenced by several genetic and metabolic factors [5], one of which may be the
vitamin D status of patients.
Vitamin D is a steroid hormone, involved in many biological processes and has a bidirectional relationship with
liver,  in  fact,  vitamin  D  production  and  activation  are  closely  regulated  by  the  liver  [6].  Indeed,  there  is  a  high
prevalence of vitamin D deficiency in liver diseases, such as alcoholic hepatitis, non-alcoholic fatty liver disease and
chronic viral hepatitis [7]. Furthermore, vitamin D deficiency is a negative prognostic factor for patients with HCV
genotype 1 infection, correlating with the severity of liver disease and a poorer response to interferon-based therapy,
with significantly lower Sustained Virologic Response (SVR) rates [8]. On the other hand, vitamin D supplementation
has been shown to complement IFN-based antiviral therapy leading to significant improvements in SVR [9]. Similar
improvements in SVR were observed in patients with HCV genotypes 2 and 3 [10]. However, a metanalysis of eleven
studies including more than 2,600 patients failed to demonstrate any association between baseline vitamin D levels and
SVR [11]. The high efficacy and excellent safety profile of DAAs have made IFN treatment of HCV infection obsolete
in many parts of the world, though the pathophysiology of hepatitis C remains linked to activation of the interferon
system [12]  and other  indications for  the use of  IFN remains,  despite  its  toxicity.  For  these reasons,  dissecting the
intricacies of the relationship between IFN and vitamin D is not futile.
The main physiological action of vitamin D is the regulation of calcium/phosphate metabolism and maintenance of
bone health; in fact, a defective vitamin D status leads to the development of a secondary hyperparathyroidism, aiming
to  maintain  calcium  levels  within  the  range  of  normality  [13].  Therefore,  the  definition  of  vitamin  D  adequacy  is
historically based upon the identification of the plasma 25(OH) vitamin D threshold able to suppress PTH synthesis. On
this basis, the threshold of 75 nmol/L (30 ng/mL) is deemed adequate for bone health [14] and the vitamin D status is
defined deficient for concentration lower than 50 nmol/L (20 ng/mL) and insufficient for 50-75 nmol/L (20-30 ng/mL)
[13]. However, there is evidence suggesting that the inverse relationship between vitamin D and PTH might be less
linear in patients affected by chronic liver disease [15].
In this study, we aimed to evaluate the effect of chronic hepatitis C on vitamin D/PTH axis and whether IFN-based
regimens have a predictable an impact on vitamin D homeostasis.
2. PATIENTS AND METHODS
We  performed  a  retrospective  study  on  the  entire  casuistry  of  patients  referred  for  antiviral  treatment  of  HCV
infection to the Liver Clinic of a University Hospital in Northern Italy, in the period between 1st October 2003 and 1st
September  2013.  In  this  study,  the  necessary  inclusion  criteria  for  each  patient  were  as  follows:  a)  chronic  HCV
infection  at  the  time  of  entry  into  the  study  (documented  by  HCV positive  viraemia)  and  absence  of  any  previous
antiviral therapeutic attempt (so-called naive patients); b) documentation of antiviral treatment with the current standard
therapy for HCV (PEG-IFN-alpha and ribavirin) for a minimum duration of at least 12 consecutive weeks, according to
the current schedule accepted in the technical data sheet (24 weeks for HCV genotypes 2 and 3, 48 weeks for genotypes
1 and 4): these therapies should be completed for at least 6 months from the date of closure of the study, according to
what is commonly expected for the minimum follow-up duration after antiviral treatment; c) availability of complete
clinical and biohumoral data both at baseline and at the time points commonly tested during antiviral treatment (in
particular  4th  (TW4)  and  12th  (TW12)  treatment  weeks  and  24  weeks  after  the  end  of  therapy);  d)  availability  of
biological  samples  at  all  aforementioned  time  points  (whole  blood,  serum  and  plasma);  e)  obtainment  of  written
informed consent from the patient to the use of biological specimens/personal sensitive data. The exclusion criteria, for
each  patient,  were  instead:  a)  lack  of  informed  consent;  b)  lack  of  completeness  of  clinical/biohumoral  data  or
biological  samples  at  the  aforementioned  time  points;  c)  presence  of  viral  co-infections  (hepatitis  B  or  human
immunodeficiency viruses) or concomitant liver tumors; chronic intake of vitamin D supplementation at the time of
entry into the study for reasons unrelated to antiviral treatment (e.g. renal insufficiency, osteoporosis). The patients
initially  selected  were  209.  Using  the  above  criteria,  the  following  patients  were  excluded  from  the  study:  N.=26
because not naive to antiviral treatment; N.=112 as no clinical data and/or complete biological samples were available;
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N.=8  as  treated  with  protease  inhibiting  drugs  (e.g.  boceprevir);  N.=5  as  treated  with  non-PEG  standard  IFN  +/-
ribavirin; N.=18 because antiviral treatment and/or related follow-up had not yet been completed as of 1st September
2013. Therefore, 40 Caucasian patients (20 F, 20 M) could be included in the study, which was conducted in strict
adherence to the principles of the Declaration of Helsinki. More in detail, 12 subjects received PEG-IFN-alpha-2a (at a
standard dose of 180 mcg/week), and 28 PEG-IFN-alpha-2b (at a dose of 1.5 µg/kg/week as per data sheet). Moreover,
27 patients received vitamin D supplementation at least four weeks before starting therapy as well as during antiviral
treatment (7500 IU/week, preceded by a loading dose of 300000 IU in the 21 subjects with a more severe deficiency);
the second group of 13 subjects did not receive any supplementation, as it was treated before 2010, when there was still
no scientific evidence of a possible gain in therapeutic response compared to the simple standard antiviral treatment [9].
Before undergoing antiviral treatment, liver disease was staged by performing Transient Elastography (TE), assessing
Liver  Stiffness  (LS),  by  a  FibroScan®  device  (Echosens,  Paris,  France).  Fibroscan  was  performed  as  reported  by
Sandrin et al. [16], using at least 10 valid measurements; examinations were considered reliable when the interquartile
range was <30% and the success rate was >60%. Furthermore, the Fibrosis-4 (FIB-4) was calculated for each patient, as
reported by Sterling et al. [17].
A fasting blood sample (EDTA) was drawn before the onset of therapy, at 4 weeks and 12 weeks and after 24 weeks
of follow-up. Plasma samples were aliquoted and stored at -80°C for subsequent analysis.
Clinical  and  laboratory  data  were  collected  in  an  electronic  database.  The  BMI  was  calculated  as  body  weight
divided by the square of the height (kg/m2). The following laboratory data were obtained:
Serum aspartate  aminotransferase  (AST),  alanine  aminotransferase  (ALT),  calcium*  and  phosphorus*  were
measured with the Advia 1800 Chemistry System (Siemens Healthcare, Germany).
Plasma 25-hydroxycholecalciferol and PTH concentrations were measured by chemiluminescence using the kits
LIASON®25 OH vitamin D TOTAL and LIASON® N-TACT® PTH II (Diasorin, Saluggia, Italy), respectively.
Local laboratory normal ranges were 30-100 ng/mL and 14.4-63.3 pg/mL, respectively.
*available in 10/40 patients
Statistical analysis was carried out using GraphPad Prism software version 6.0 for Mac OS X (GraphPad Software,
La Jolla, CA, USA, www.graphpad.com). Data distribution was analyzed with the Shapiro-Wilk test, rejecting the null
hypothesis (Gaussian distribution). Accordingly, the measures of centrality and dispersion used throughout the paper to
describe continuous variables are medians and Interquartile Ranges [IQR], while categorical variables are shown as
frequencies  (%).  Plasma  25(OH)  vitamin  D and  PTH concentration  at  different  time  points  were  compared  by  the
Wilcoxon test for paired samples. Plasma 25(OH) vitamin D and PTH concentrations between supplemented and non-
supplemented  patients,  and  the  kinetics  of  the  plasma  levels  of  vitamin  D  and  PTH  between  responders  and  non-
responders to antiviral treatment were compared by the Mann-Whitney test. We used the Spearman’s correlation to test
the  association  between  25(OH)  vitamin  D  and  PTH  plasma  levels  and  between  the  severity  of  liver  fibrosis  and
25(OH)  vitamin  D  and  PTH  levels.  The  modifications  of  25(OH)  vitamin  D  and  PTH  plasma  levels  according  to
different seasons were tested with the Chi-Square test. In order to verify the relationship between selected dichotomous
dependent  variables  (Rapid  Virological  Response  (RVR),  SVR)  and  a  set  of  independent  predictive  variables,  a
stepwise logistic regression analysis was conducted with a forward approach.
The threshold value chosen to indicate the statistical significance was 0.05 (two tails) for all the analyses.
3. RESULTS
3.1. 25 (OH) Vitamin D Concentration
In Table 1, we report the main demographic and clinical features of the study population, which were consistent
with the characteristics of patients with well-compensated chronic hepatitis C in Italy.
In Fig. (1a) we present the scatterplot of plasma vitamin D concentrations at baseline; 27/40 (67.5%) patients had an
inadequate vitamin D status, 6/40 (15%) having vitamin D insufficiency and 21/40 (53%) vitamin D deficiency.
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Table 1. Main demographic and clinical characteristics of population studied. Continuous variables are shown as medians
[IQR], while categorical variables are presented as frequencies (%).
Variable N.=40
Age, years 53 [45-64]
Male gender, N. 20 (50)
Body Mass Index, kg/m2 25.0 [22.6-27.1]
Aspartate aminotransferase, U/L 36 [25-62]
Alanine aminotransferase, U/L 49 [32-89]
Platelet Count, ×109/L 196 [146-238]
FIB-4, ≤3.25 / >3.25 30 (75) / 10 (25)
Liver Stiffness, kPa 7.0 (4.6-10.4)
Viral genotype
          HCV-1
          HCV-2
          HCV-3





Serum HCV RNA, IU/mL (×106) 1.73 [0.45-7.55]
Serum 25-hydroxycholecalciferol, ng/mL 19.3 [13.8-33.4]
Serum PTH, pg/mL 33.7 [26.3-53.1]
Fig. (1). Plasma vitamin D in the study population. In panel (a), we report the box and whisker plot of vitamin D concentration in the
general population. In panel (b), the histogram reports the median and the respective IQR of vitamin D concentration at the different
time points (follow-up: 24 weeks after the end of treatment). In panel (c) we report the median vitamin D plasma concentration in
supplemented patients (grey bars) and in not supplemented patients (white bars), at different time points.
In Fig. (1b) we report the median plasma 25(OH) vitamin D concentrations at TW4 and TW12 and in the follow-up,
which were, respectively 41.1 [25.3-47.6] ng/mL, 36.6 [26.1-43.3] ng/mL and 26.0 [19.5-32.6] ng/mL. Considering the
entire study population, 25(OH) vitamin D plasma concentration increased significantly at TW4 (p=0.002) and TW12
(p=0.004), returning to values comparable to baseline in the follow-up period (p=0.31). However, as expected, only
patients  who  underwent  cholecalciferol  supplementation  showed  an  increase  in  plasma  vitamin  D  concentration
(difference between the two groups: p=0.005 at the analysis of the variance for repeated measurements); in fact, as
shown in Fig. (1c), the supplemented group ameliorated vitamin D status from baseline (16.2 [12.0-28.4] ng/ml) to
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TW4 (44.2 [35.1-52.9] ng/mL; p=0.0002) and TW12 (40.3 [29.6-47.2] ng/mL; p=0.0002);  at  the end of follow-up,
25(OH) vitamin D plasma concentration returned to values comparable to those observed at baseline (26 [21.4-33.4]
ng/mL;  p=0.05).  Conversely,  those  who  did  not  receive  vitamin  D  supplementation  showed  a  slight,  though  not
statistically  significant  decrease  in  vitamin  D  plasma  concentration  from  baseline  (32.9  [15.5-42.8]  ng/mL):  (22.8
[18.3-33.1] ng/mL at TW4, 23.3 [17.2-34.5] ng/mL at TW12, 25.0 [15.9-30.6] ng/mL at follow-up. At the end of the
follow-up, no differences could be demonstrated between groups. No significant correlation between the severity of
liver fibrosis and vitamin D concentrations could be observed at any time point. No significant correlation was also
observed  between  the  observed  delta  of  vitamin  D (arbitrarily  defined  by  us  as  a  positive  or  negative  variation  of
vitamin D ≥20 ng/mL) and SVR (p=0.21).
3.2. PTH Concentration
Blood  PTH  concentration  was  determined  at  the  same  time-points.  The  median  PTH  plasma  concentration  at
baseline was 33.7 [26.3-53.3] pg/mL (Figs. 2a and b). In 39/40 (98%) of patients, PTH levels were below the threshold
for hyperparathyroidism. Interestingly, we did not observe a statistical correlation between vitamin D and PTH blood
levels (ρ=-0.07; p=0.65). The median PTH plasma concentration significantly increased from baseline during treatment,
raising to 44.8 [30.7-57.2] pg/mL at TW4 (p=0.01), and to 47.0 [37.1-63.2] pg/mL at TW12 (p=0.006), returning to
values  in  the  follow-up  (34.5  [27.6-43.0]  pg/mL;  p=0.16);  specifically,  in  N.=6  and  N.=10  patients  plasma  PTH
increased at TW4 and at TW12, respectively. The proportion of patients satisfying criteria for hyperparathyroidism was
higher  at  12  weeks  (N.=10  25%)  than  at  4  weeks  (N.=6  15%).  At  the  end  of  follow-up  2  patients  (5%)  still  had
hyperparathyroidism. Interestingly, vitamin D supplementation did not significantly affect PTH plasma concentration,
as shown in Fig. 2c; in fact, PTH plasma concentration was similar in the two groups (vitamin D supplemented; not
supplemented)  at  each  time  points.  No  significant  correlation  between  the  severity  of  liver  fibrosis  and  PTH
concentrations could be observed at any time point. No significant correlation was also observed between the observed
delta of PTH (arbitrarily defined by us as a positive or negative variation of PTH ≥4 pg/mL) and SVR (p=0.91).
Fig. (2). Blood parathyroid hormone (PTH) levels in the studied population). a) The graph shows the median value of PTH and bars
indicate the 99th and 1st percentiles. Dots represent the values of single patients (N.=40). b) In the histogram are reported the median
and the respective upper e lower values of PTH of all patients before (baseline), 4 weeks and 12 weeks after the beginning of the
therapy and 24 weeks after the end of the anti-viral therapy (follow-up). c) Median with upper and lower values of PTH in patients
supplemented (grey bars; N.=27) or not supplemented (white bars; N.=13) with vitamin D before (baseline), 4 weeks and 12 weeks
after the beginning of the therapy and 24 weeks after the end of the anti-viral therapy (follow-up).
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3.3. 25 (OH) Vitamin D and PTH Concentrations According to Seasons
According to the Societas Meteorologica Palatina classification which has been followed since 1780 by professional
meteorologists,  for  temperate  areas  in  the  Northern  hemisphere  (where  the  present  study  was  conducted),
meteorological  seasons  have  the  following  durations:  spring  begins  on  1  March,  summer  on  1  June,  autumn  on  1
September, and winter on 1 December. Start of antiviral therapy was as follows in our casuistry of patients: spring:
N.=7;  summer:  N.=4;  autumn:  N.=17;  winter:  N.=12.  There  was  a  trend  towards  a  seasonal  influence  on  25(OH)
vitamin D plasma concentrations (p=0.057), while PTH showed no significant seasonal modifications (p=0.3).
3.4. Hepatitis C Virological Outcomes and Relationship With Vitamin D/PTH Levels
Twelve patients (30%) obtained a rapid virological response (RVR, i.e. a negative HCV RNA at TW4); 31 (77%)
patients  achieved  a  complete  early  virological  response  (cEVR,  i.e.  a  negative  viraemia  at  TW12).  The  treatment,
according  to  the  technical  schedule  for  the  different  genotypes,  was  completed  by  38  patients  (95%).  A  similar
percentage was found with regard to the virological response at the end of therapy (ETR): 95% (38/40). All patients
completed the planned follow-up of 24 weeks after the end of treatment. The final percentage of SVR was 80% (32/40),
since 6 relapses (15%) occurred, with the following rates in genotype 1, 2, 3 and 4 respectively: 60%, 84%, 100%,
100%.
The  comparison  between  the  vitamin  D  supplemented  group  and  the  control  arm  with  the  Mann-Withney  test
showed no significant differences in RVR (respectively 7/13 vs. 5/27, p = 0.07), ETR (12/13 vs. 26/27, p=0.42), SVR
(9/13 vs. 22/27, p=0.41), and relapse (2/13vs. 4/27, p=0.48) rates. Similarly, no significant correlation was observed
between the delta of PTH and RVR (p=0.38 at the Mann-Whitney test) or SVR (p=0.91 at the Mann-Whitney test).
Neither basal vitamin D nor PTH levels demonstrated to be good independent variables when a logistic regression
analysis  was  conducted,  considering RVR as  a  dependent  variable  and parameters  such as  a  viral  genotype,  IL28b
genotype 9860 and advanced fibrosis as other independent variables. The same was true when SVR was considered as a
dependent variable.
4. DISCUSSION
In the present paper, we demonstrate that an increase in plasma PTH concentration is to be expected to occur in
most patients who undergo an IFN-based antiviral regimen to treat HCV, up to one-quarter of whom will reach PTH
values  consistent  with  secondary  hyperthyroidism.  This  effect  is  not  prevented  by  the  correction  of  an  associated
vitamin D deficiency. The possibility of inducing secondary hyperparathyroidism should be considered among the side
effects  of  IFN treatment;  this  issue  needs  to  be  discussed  at  the  light  of  the  knowledge  of  IFN actions  and  of  the
complex control of hormones regulating mineral bone metabolism and calcium homeostasis.
The antiproliferative actions of  IFN, a  cytokine with multiple  effects  on different  cell  lineages,  have long been
known. IFN was considered a “miracle drug for cancer” long before the current era of biologics and target therapies.
The  authors  are  well  aware  however  that  in  recent  years,  the  importance  of  IFN-based  therapies  has  been  greatly
reduced  in  medical  therapy,  remaining  at  the  moment  the  prerogative  of  a  few  morbid  conditions  such  as  chronic
myeloid leukemia and rare cases of solid neoplasms (e.g. non-muscle invasive bladder cancer and renal carcinoma). In
the hepatological field, IFN has been a partner in the treatment of HCV for three decades and has played an important
role in curing many patients and reducing their subsequent risk of cirrhosis or hepatocellular carcinoma. More recently,
it has indeed been supplanted, at least in most countries with highest gross domestic product per capita, by the much
more effective and tolerable treatments with DAAs, while it still plays a marginal role in the treatment of hepatitis B
and D. However, it should not be forgotten that penetration of new interferon-free therapies into standard management
plans in so-called less developed countries, which account for two thirds of the world total population, has been very
slow: the delay in making these drugs available to patients is their high cost which is still limiting uptake, irrespective
of whether funding is patient-based or by government reimbursement. As a matter of fact, the Asian Pacific Association
for the Study of the Liver (APASL) still considers PEG-interferon + ribavirin as a valid, although of the second choice,
option in DAA-unaffordable countries, especially in genotype 1 and 4 naive patients [18].
In  any case,  the  objective of  the  present  study,  which is  based on a  historical  casuistry,  was not  to  analyze the
clinical efficacy of a treatment as dated as PEG-IFN-alpha, but to analyze possible strange and unexpected effects of
such a therapy that has been shown over the years to have pleiotropic effects both in a positive and negative sense.
More specifically, we tested how this therapy modifies the homeostasis of vitamin D and PTH (and therefore also of
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calcium and phosphorus) and, from this specific point of view, therefore, our study is to be considered innovative. We
were in fact intrigued that unexpectedly we found a gap in the medical literature for what concerns with the specific
item.  Indeed,  the  first  clinical  works  suggesting  a  possible  gain  in  effectiveness  if  there  were  a  concomitant
supplementation of vitamin D to PEG-IFN based regimes were not followed, at least to the best of our knowledge, by
any basic or translational study aimed at explaining the possible underlying physiopathological mechanisms. In any
case,  being  strong  inhibitory  of  fibroblasts  and  of  collagen  synthesis,  it  is  conceivable  that  IFN  may  affect  bone
metabolism, although to what extent and even in which direction is controversial. For example, there have been reports
showing that osteoblasts and bone deposition but also osteoclasts and bone resorption are inhibited by IFN in vitro.
Moreover, children undergoing IFN treatment for hepatitis B have significantly higher PTH levels but also higher bone
mineral  density  than  age-matched  healthy  controls.  In  another  small  study  (N.=19),  crosslinked  telopeptide  type-I
collagen  levels  decreased  significantly  after  IFN treatment  for  essential  thrombocythemia.  In  the  same study,  both
vitamin  D  and  PTH  were  numerically  but  not  statistically  higher  after  treatment  than  pre-treatment;  interestingly,
however, post-treatment serum calcium concentrations were inversely related to the cumulative IFN dose received [19].
These findings were interpreted by the authors as suggestive of modulation of bone remodelling with suppression of the
resorption sequence during IFN treatment.
Two-thirds of the patients that we report here were vitamin D deficient or insufficient, a proportion in line with
other  studies  considering  the  30  ng/mL  cutoff  to  define  normal  values  [20].  It  is  well  known  that  vitamin  D  is
dysregulated in chronic liver disease as well as in other inflammatory diseases [21], an observation which does not
necessarily translate into an improvement of these diseases following the correction of vitamin D deficit. In fact, the
authors of a recent Cochrane review, based on 15 randomized trials comprising 1,034 patients with the chronic liver
disease, could not decide whether vitamin D supplements have an important effect on all-cause mortality, liver-related
mortality, or on serious or non-serious adverse events [22]. This issue cannot thus certainly be settled by the present
data. More modestly, here we intended to ascertain what happens to the vitamin D/PTH balance when IFN is given to
patients with or without supplementation with vitamin D. Active vitamin D acts as a negative regulator of PTH gene
expression,  though  through  incompletely  understood  mechanisms  [23].  On  the  other  hand,  with  a  classic  negative
feedback mechanism, PTH converts 25-hydroxyvitamin D to its most active metabolite, 1,25-dihydroxyvitamin D-3, by
activation of the enzyme 1-hydroxylase in the proximal tubules of the kidney. The present series demonstrate clearly
that  vitamin  D  supplementation  does  not  prevent  IFN-induced  PTH  increase.  In  fact,  there  were  no  significant
differences in PTH levels between patients supplemented or not with vitamin D. This finding is at variance with what
occurs in other kinds of secondary hyperparathyroidism, where vitamin D helped in the regulation of PTH levels in a
dose-dependent manner [24]. The benefits of cholecalciferol supplementation are apparent in rheumatoid arthritis [25],
where a correlation exists between vitamin D levels and secondary hyperparathyroidism [26]. In other words, the tightly
controlled feedback cycle between PTH and vitamin D does not seem to be operating in the setting we studied. We can
only speculate why.
Under  physiological  conditions,  a  crosstalk  exists  between  PTH  and  vitamin  D,  resulting  in  a  classic  negative
feedback loop. PTH increases the level of CYP27B1, the gene coding for 1-alpha-hydroxylase that converts vitamin D
in its active form, i.e., 1,25 vitamin D. In turn, stimulation of the vitamin D receptor on parathyroid gland cells by 1,25
vitamin D decreases PTH synthesis and secretion, inhibits PTH cell proliferation, and increases the expression of the
calcium-sensing receptor. Both PTH and 1,25 vitamin D act in concert with the more recently discovered fibroblast
growth factor 23 (FGF23) and Klotho [27]. When PTH binds to the PTH receptor, the signal transduction implicates an
increase in FGF23 secretion by bone cells into the bloodstream. FGF23 in the circulation finds its receptors Klotho
(which build a complex with FGF23 receptor 1) also on parathyroid cells.  When activated by FGF23, the complex
Klotho/FGF23R1 inhibits PTH synthesis and, consequently, PTH secretion into the blood circulation (Fig. 3a).
This is one, among several mechanisms, that allows the organism to maintain a balance and PTH in a normal range.
We propose that the increase in PTH observed after PEG-IFN-α is caused by interference with this latter pathway,
although we can only provide clues for this hypothesis. In fact, PTH receptor expression on the plasma membrane of a
bone cell  line is  reduced by interferon [28].  A significant lower expression of PTH receptors is  expected to impair
FGF23 secretion that would result in a reduction of FGF23-mediated PTH release inhibition on parathyroid gland cells.
The final effect would be a significant increase in PTH levels resulting in drug-induced secondary hyperparathyroidism
(Fig. 3b). Another clue is that low-dose IFN-α inhibits melanoma cell proliferation by interference with the autocrine
growth circuit of FGF-2, a fibroblast growth factor belonging to the same family [29], an effect recently exploited to
suppress FGF-2 in patients with metastatic melanoma [30].
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Fig. (3). Representative scheme of PTH pathway regulation. a) PTH regulation in physiological condition. b) speculation of PTH de-
regulation pathway in the presence of PEG-IFN-α treatment for chronic hepatitis C patients.
CONCLUSION
In conclusion, for the first time, we show that PEG-IFN-α treatment is consistently associated with increased PTH
levels and, often, secondary hyperparathyroidism that is not prevented by vitamin D. The mechanism might involve an
interaction with other PTH regulatory hormones, a hypothesis that needs to be tested in specifically designed studies.
Meanwhile, we caution clinicians using PEG-IFN-α to consider secondary hyperparathyroidism among the long list of
possible side effects of this drug.
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